This week the US Food and Drug Administration approved the release of fingolimod (trade name Gilenya®), the first oral medication for the treatment of remitting relapsing multiple sclerosis. Swedish Neuroscience Institute is proud to have participated in the pivotal clinical trial that led to the approval of Gilenya. Gilenya is a welcome addition to the set of medications available to patients living with MS. There are currently five injectable therapies and two intravenous therapies approved by the FDA for the treatment of MS. Although these treatments are very effective, many patients have been hoping for an oral alternative. Some patients are finding that they have “injection fatigue” or are running out of places to inject the medication. It is important to note, however, that not all patients should switch to Gilenya. Patients with stable disease should remain on their medications. Patients need to be informed of the risks associated with Gilenya, including slowed heart rate, increased blood pressure, difficulty breathing, abnormal liver function, and infection, and how these risks may apply to them. If you are wondering whether Gilenya is right for you, please ask your neurologist.
Most Recent Articles
What to know about the Delta variant: Infectious disease experts weigh in
The COVID-19 Delta variant is quickly becoming the most common strain in the U.S. Discover how you can stay safe and protect your loved ones.
Caring for BIPOC and minority mental health
Access mental health resources at Swedish, and in our community
Depression before and after birth: You are not alone
Millions of women struggle with anxiety, depression and mental health issues during pregnancy and after childbirth. Find ways to cope.
Investing in our community to change lives
Learn why Swedish partners with local organizations to bring critical services into communities where help is needed most.
Do you know how to protect your skin from the summer sun?
Learn how to enjoy the sun safely – including how to protect against skin cancers such as melanoma – with these tips.
Lifting COVID-19 restrictions: Q&A with Swedish experts
With more people in Washington getting vaccinated, restrictions are lifting. Our experts discuss how to keep yourself and others safe.
Are you languishing?
Feeling a little blergh? Neither good nor sad and sort of on autopilot? Get tips from a behavioral health specialist to move from languishing to flourishing.
Pride Month Caregiver Spotlights
We're spotlighting some of our amazing caregivers and sharing what Pride Month means to them.
A cancer survivor's quest to help others beat chemo brain
National Cancer Survivors Day honors people like Katie Henry, who joined the VIBE study at Swedish to beat chemo brain. Here’s her story and memory strategies, too.
New research brings hope for detecting and preventing Alzheimer’s disease
A new blood test to detect Alzheimer’s disease is on the horizon, and recent research shows how you can lower your risk for the disease.
Working toward more compassionate and inclusive care for the LGBTQIA+ community
Learn how Swedish is taking steps to create a safer and more inclusive environment for gender-diverse patients through its LGBTQI+ Initiative.
Have you been putting off your annual men’s wellness exam?
What better way to celebrate Men’s Health Month than by scheduling much needed (and often dreaded) healthcare appointments?
Let us continue on the journey toward equity and justice
A statement from our chief diversity, equity, and inclusion officer
After massive heart attack, ECMO saved Vivek's life
Swedish is one of only two hospitals in Washington to offer novel therapy that allows heart and lungs to rest and heal